MARKETS / NYSE / GKOS
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Glaukos Corp. GKOS

13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$507.4M
▲ 32.3% vs FY2024
EPS · FY25
$-3.28
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-26.4%
Net margin · FY25
-37.0%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 507.4M
Revenue, FY2025 · full 13-year series below
Revenue Net income
0.20.40.60.5-0.220132016201920222025
0.20.40.60.5-0.22016201920222025

The company lost 37 cents on every revenue dollar this year.

Per share
USD -3.28
Diluted EPS, FY2025
EPS
0.40.81.2-3.2820132016201920222025
0.40.81.2-3.282016201920222025

The company pays no cash dividend.

Profitability
-26.4%
Return on equity, FY2025
ROE
246-26.4%20132016201920222025
246-26.4%2016201920222025
Operating margin-39.3%
Net margin-37.0%
Return on assets-20.1%

Each USD of equity lost 26 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+17.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+21.5%
+17.7%
+21.6%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.06B
Shares outstanding, FY2025
0.000.0620132016201920222025
0.030.062016201920222025
Change, 5 years+27.1%
Change, 10 years+78.7%

The share count grew 27% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 893.5M
total assets, end of FY2025
Total assetsUSD 893.5M
EquityUSD 656.2M
CashUSD 90.8M
Current ratio4.69×

Equity funds 73% of total assets.

History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.5
0.4
0.3
0.3
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.0
0.0
Operating income $B
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.28
−2.77
−2.78
−2.09
−1.07
−2.70
0.37
−0.37
0.00
0.12
−2.13
−5.29
−6.21
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−26.4
−23.8
−27.2
−17.8
−7.9
−18.0
3.6
−8.3
−0.1
4.3
·
·
·
Shares out B
0.06
0.06
0.05
0.05
0.05
0.05
0.04
0.04
0.03
0.03
0.03
0.00
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
48 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 1 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed